The authorized capital of the Company consists of an unlimited number of voting common shares and preferred shares with no par value.

On July 12, 2019, the Company approved a 1.6 to 1 share split of the Company’s issued and outstanding common shares (the “Share Split”). Each shareholder of record of the Company as of the close of business on the record date on July 22, 2019 received 1.6 common shares for each share held on such date. All references to common shares, warrants, simple warrants and performance warrants have been retrospectively adjusted to reflect the Share Split.

		December 31, 2020						December 31, 2019
	Note	Number of Shares			Carrying Amount			Number of Shares		Carrying Amount
Balance, beginning of year			107,180,423			509,654			68,648,984		65,133
Initial public offering			—			—			11,000,000		189,518
Shares issued for assets			—			—			797,952		6,537
Share issuances			337,696,867			176,931			394,926		2,323
Shares issued to related parties			—			—			3,730,963		63,460
Share issuance costs			—			(5,593	)		—		(12,770	)
Business acquisitions			—			—			2,696,800		39,849
Disposition of Bridge Farm	5		(2,716,271	)		(38,447	)		—		—
Convertible debt - conversions	16		373,371,318			63,002			13,108,676		113,526
Derivative warrants exercised	17		102,836,429			55,912			—		—
Warrants exercised			—			—			4,551,082		21,882
Shares issued for services			—			—			164,080		2,320
RSUs exercised	22(c)		475,367			587			57,960		195
Employee warrants exercised			—			—			2,029,000		17,681
Balance, end of year			918,844,133			762,046			107,180,423		509,654

On August 18, 2020, the Company issued 25.8 million Series A Units (the “Series A Units”), each consisting of one common share and one Series A Warrant (collectively, the “Series A Warrants”) (note 17d) to purchase one common share and 14.3 million Series B Units (the “Series B Units”), each consisting of one pre-funded Series B Warrant (the “Series B Warrants”) to purchase one common share and one Series A Warrant to purchase one common share (note 17d). Each Series A Unit was sold at a price of US$0.50 per unit and each Series B Unit was sold at a price of US$0.50 per unit, less US$0.0001 per unit. Gross proceeds from this offering were US$20 million. The Series A Warrants and Series B Warrants were exercisable immediately and have a term of five years commencing on the date of issuance. The exercise price of the Series A Warrants was US$0.75 per common share and the exercise price of the Series B Warrants was US$0.0001 per common share.

On August 19, 2020, 9.2 million Series B Warrants were exercised resulting in the issuance of 9.2 million common shares and on August 20, 2020, the remaining 5.1 million Series B Warrants were exercised resulting in the issuance of 5.1 million common shares.

On August 13, 2020, the Company entered into an equity distribution agreement to establish the ATM Program which allowed the Company to offer and sell common shares having an aggregate offering price of up to US$50 million. During the period from October 5, 2020 to December 4, 2020, the Company issued 153.5 million common shares at a weighted average exercise price of US$0.3250 for gross proceeds of US$49.9 million.

On December 4, 2020, the Company entered into an equity distribution agreement to establish a new ATM Program which allowed the Company to offer and sell common shares having an aggregate offering price of up to US$150 million. During the period from December 14, 2020 to December 31, 2020, the Company issued 156.3 million common shares at a weighted average exercise price of US$0.4795 for gross proceeds of US$75.0 million. Subsequent to December 31, 2020, the Company issued 117.6 million common shares at a weighted average exercise price of $US0.6379 for gross proceeds of US$75.0 million.

Subsequent to December 31, 2020, on January 11, 2021 the Company entered into an equity distribution agreement to establish a third ATM Program having an aggregate offering price of up to US$50.0 million. Under the third ATM Program, from January 11, 2021 to January 13, 2021 the Company issued 72.4 million common shares at a weighted average exercise price of US$0.6903 for gross proceeds of US$50.0 million.

Subsequent to December 31, 2020, on January 20, 2021 the Company entered into an equity distribution agreement allowing it to issue common shares in an amount up to US$400 million at its discretion and established an ATM Program covering issuances of up to US$400 million. Under this ATM Program, the Company issued 237.7 million common shares at a weighted average exercise price of US$0.6325 for gross proceeds of US$150.3 million. Under this equity distribution agreement, the Company also completed two registered offerings (note 34).

	Number of Warrants			Carrying Amount
Balance at December 31, 2018		4,211,904			3,108
40% Warrants reclassified from derivative liability⁽ⁱ⁾		957,225			4,122
60% Warrants reclassified from derivative liability⁽ⁱ⁾		1,495,665			11,969
Warrants issued to related parties⁽ⁱⁱ⁾		480,000			5,833
Warrants issued on conversion of convertible notes⁽ⁱⁱⁱ⁾		3,572,274			6,731
Warrants exercised		(4,551,082	)		(3,931	)
Warrants expired		(662	)		(1	)
Balance at December 31, 2019		6,165,324			27,831
Warrants issued		544,000			306
Warrants expired		(3,232,434	)		(5,908	)
Warrants cancelled		(2,452,890	)		(16,091	)
Balance at December 31, 2020		1,024,000			6,138

During the year ended December 31, 2020, the warrants issued upon conversion of the CAD and USD denominated convertible notes expired, and the 40% Warrants and 60% Warrants issued as part of the term debt financing were surrendered and cancelled.

During the year ended December 31, 2019, a total of 4,551,082 warrants were exercised consisting of 4,211,242 warrants exercised at a price of $3.91 for gross proceeds of $16.5 million, 307,840 exercised for gross proceeds of $1.3 million of the warrants issued upon conversion of the CAD denominated convertible notes and 32,000 warrants exercised for gross proceeds of USD$120 thousand of the warrants issued upon conversion of the USD denominated convertible notes. 662 warrants expired unexercised in April 2019. The carrying value of the exercised warrants of $3.9 million was adjusted from warrants to share capital.

	Warrants outstanding and exercisable
Issued in relation to	Weighted average exercise price		Number of warrants		Weighted average contractual life (years)
Convertible notes (USD)	USD 3.75			444,888		0.8
Convertible notes (CAD)		4.38		2,787,546		0.7
Acquisition of financial obligation		15.94		480,000		2.5
Term debt financing (60%)		20.76		1,495,665		2.6
Term debt financing (40%)		21.63		957,225		2.6
		11.97		6,165,324		1.6